NICE tackles "major challenge" of radical colorectal cancer therapy costs
This article was originally published in Clinica
The early diagnosis of suspicious symptoms, variations in care policy and the "major economics challenge" posed by radical therapies are among the issues that the UK's National Institute for Health and Clinical Excellence (NICE) will focus on to develop a clinical practice guideline for colorectal cancer. Its proposed scope is now out for consultation, until March 18.
You may also be interested in...
The physician who led the first first-in-human robotic-assisted neurovascular intervention with Corindus’ CorPath GRX system believes the technology could revolutionize neurovascular intervention by allowing a centralized interventional team to remotely treat patients.
The disruptive medtech M&A of recent years was not matched in the past year for volume, but there were isolated outbreaks of major activity, as shown in our company rankings.
Hikma and Civica Rx have announced the launch of a first wave of eight essential injectable medicines, including heparin, as part of a deal struck between the two firms earlier this year.